|
|
|
|
Vol. 301, Issue 3, 1157-1165, June 2002
Department of Laboratory Medicine, Kumamoto University School of
Medicine, Kumamoto, Japan
We previously reported that ranitidine, an H2 receptor
antagonist, inhibited neutrophil activation in vitro and in vivo,
contributing to reduce stress-induced gastric mucosal injury in rats.
In this study, we examined whether ranitidine would reduce
ischemia/reperfusion-induced liver injury, in which activated
neutrophils are critically involved, in rats. We also examined the
effect of famotidine, another H2 receptor antagonist, on
leukocyte activation in vitro and after ischemia/reperfusion-induced
liver injury in rats to know whether inhibition of neutrophil
activation by ranitidine might be dependent on its blockade of
H2 receptors. Ranitidine inhibited the activation of
neutrophils in vitro as reported previously, whereas famotidine significantly enhanced it. Ranitidine inhibited the production of tumor
necrosis factor-
(TNF-
) in monocytes stimulated with lipopolysaccharide in vitro, whereas famotidine did not. Although hepatic ischemia/reperfusion-induced increases in hepatic tissue levels
of TNF-
, cytokine-induced neutrophil chemoattractant, and hepatic
accumulation of neutrophils were inhibited by intravenously administered 30 mg/kg ranitidine, these increases were significantly enhanced by 5 mg/kg i.v. famotidine. The decreases in both hepatic tissue blood flow and bile secretion and the increases in serum levels
of transaminases seen after reperfusion were significantly inhibited by
ranitidine, whereas these changes were more marked in animals given
famotidine than in controls. These observations strongly suggested that
ranitidine could reduce ischemia/reperfusion-induced liver injury by
inhibiting neutrophil activation directly, or indirectly by inhibiting
the production of TNF-
, which is a potent activator of neutrophils.
Furthermore, the therapeutic efficacy of ranitidine might not be
explained solely by its blockade of H2 receptor.
This article has been cited by other articles:
![]() |
X. Deng, J. P. Luyendyk, P. E. Ganey, and R. A. Roth Inflammatory Stress and Idiosyncratic Hepatotoxicity: Hints from Animal Models Pharmacol. Rev., September 1, 2009; 61(3): 262 - 282. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Deng, J. Lu, L. D. Lehman-McKeeman, E. Malle, D. L. Crandall, P. E. Ganey, and R. A. Roth p38 Mitogen-Activated Protein Kinase-Dependent Tumor Necrosis Factor-{alpha}-Converting Enzyme Is Important for Liver Injury in Hepatotoxic Interaction between Lipopolysaccharide and Ranitidine J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 144 - 152. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Malagelada, X. Xifro, N. Badiola, J. Sabria, and J. Rodriguez-Alvarez Histamine H2-Receptor Antagonist Ranitidine Protects Against Neural Death Induced by Oxygen-Glucose Deprivation Stroke, October 1, 2004; 35(10): 2396 - 2401. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Luyendyk, J. F. Maddox, G. N. Cosma, P. E. Ganey, G. L. Cockerell, and R. A. Roth Ranitidine Treatment during a Modest Inflammatory Response Precipitates Idiosyncrasy-Like Liver Injury in Rats J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 9 - 16. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Timmins, K. Hirota, and T. Kushikata Preanaesthetic H2 antagonists for acid aspiration pneumonia prophylaxis. Is there evidence of tolerance? Br. J. Anaesth., September 1, 2003; 91(3): 446 - 447. [Full Text] [PDF] |
||||
![]() |
D. A. Bull and J. Maurer Aprotinin and preservation of myocardial function after ischemia-reperfusion injury Ann. Thorac. Surg., February 1, 2003; 75(2): S735 - 739. [Abstract] [Full Text] [PDF] |
||||